RECRUITING

Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.

Official Title

Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

Quick Facts

Study Start:2022-08-10
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05535894

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of pancreatic cancer based on clinical, radiological, or pathological assessment;
  2. * Referred for abdominal and/or back pain due to pancreatic cancer;
  3. * No prior history of RFA;
  4. * Cancer pain unresponsive to the WHO 3-step analgesic ladder;
  5. * Willingness to consent to participate in the study.
  1. * Patients who are not willing to give informed consent or agree to participate in the study
  2. * Surgically resectable pancreatic cancer;
  3. * Abdominal pain with etiology other than pancreatic malignancy;
  4. * Evidence of concurrent infection;
  5. * Patients with irreversible coagulopathy international normalized ratio \>1.5 or platelet count \<50,000/mm3),
  6. * Patients with a preliminary diagnosis of adenocarcinoma are not possible established with intraprocedural at EUS-guided FNA.

Contacts and Locations

Study Contact

Shailendra Singh, MD
CONTACT
3042934123
shailendra.singh@hsc.wvu.edu
Arunkumar Krishnan
CONTACT
3042937495
arunkumar.krishnan@hsc.wvu.edu

Principal Investigator

Shailendra Singh, MD
PRINCIPAL_INVESTIGATOR
West Virginia University

Study Locations (Sites)

Shailendra Singh
Morgantown, West Virginia, 26508
United States

Collaborators and Investigators

Sponsor: West Virginia University

  • Shailendra Singh, MD, PRINCIPAL_INVESTIGATOR, West Virginia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-10
Study Completion Date2025-12

Study Record Updates

Study Start Date2022-08-10
Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

  • Pancreatic Cancer